Investing in biotech investors tracking biotech should note

Investors tracking biotech should note that CRISPR-focused companies surged 5% in Wednesday’s session, as gene-editing data from Phase II trials impressed analysts. The sector’s short-term technical charts show bullish breakouts above 50-day moving averages, suggesting momentum buying opportunities. Fundamental catalysts remain strong amid rising venture funding. Compare those two small frys to the nearly $6 billion Nasdaq Biotechnology iShares ETF (IBB), and the biotech industry’s look totally changes. IBB is a top-heavy ETF, like so many large-cap funds now. Tori Brovet is a content development editor for Morningstar. The biotech ETF (IBB) gained 2.1% yesterday on news of promising Alzheimer’s drug data. Analysts are revising price targets upward, citing statistical significance in trial endpoints. This could signal further sector-wide rallies as investor confidence grows.